NASDAQ:IMTX Immatics (IMTX) Stock Price, News & Analysis $7.59 -0.85 (-10.07%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$7.59 0.00 (0.00%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Immatics Stock (NASDAQ:IMTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immatics alerts:Sign Up Key Stats Today's Range$7.40▼$8.5750-Day Range$7.59▼$9.7752-Week Range$7.40▼$12.41Volume1.26 million shsAverage Volume703,809 shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$20.60Consensus RatingModerate Buy Company Overview Immatics N.V. (NASDAQ: IMTX) is a biotechnology company focused on developing T cell receptor (TCR)-based therapies for the treatment of cancer. The company identifies cancer targets and designs treatments intended to direct a patient’s immune system toward tumor cells, including solid tumors that may be difficult to address with conventional immunotherapies. Immatics’ technology platforms support several therapeutic approaches, including TCR-engineered T-cell therapies and TCR-based bispecific molecules that can engage both cancer targets and T cells. Its product pipeline has included candidates directed at targets such as PRAME, a tumor-associated antigen expressed in multiple cancers. The company also uses its target-discovery and validation platforms to identify and evaluate cancer antigens for potential drug development. Founded in 2000 and headquartered in Tübingen, Germany, Immatics has expanded its operations internationally, including a presence in the United States. The company develops therapies independently and through collaborations with pharmaceutical and biotechnology partners. Immatics is led by Chief Executive Officer Harpreet Singh, who has been associated with the company since its early development.AI Generated. May Contain Errors. Read More Immatics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreIMTX MarketRank™: Immatics scored higher than 69% of companies evaluated by MarketBeat, and ranked 205th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingImmatics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialImmatics has a consensus price target of $20.60, representing about 171.4% upside from its current price of $7.59.Amount of Analyst CoverageImmatics has only been the subject of 1 research reports in the past 90 days.Read more about Immatics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immatics are expected to decrease in the coming year, from ($2.00) to ($2.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is -4.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is -4.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmatics has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immatics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.36% of the float of Immatics has been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 8.27.Change versus previous monthShort interest in Immatics has recently decreased by 8.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.17 News SentimentImmatics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Immatics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for IMTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Immatics to their MarketBeat watchlist in the last 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $7,499,991.00 in company stock, which represents 0.7229% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,499,991.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders3.30% of the stock of Immatics is held by insiders.Percentage Held by Institutions64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immatics' insider trading history. Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMTX Stock News HeadlinesImmatics (NASDAQ:IMTX) & Mirum Pharmaceuticals (NASDAQ:MIRM) Critical ContrastSeptember 30 at 5:58 AM | americanbankingnews.comImmatics (NASDAQ:IMTX) Stock Bumped Up to "Hold" by Wall Street ZenSeptember 26, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Immatics and 4 more stocks see action from activist investorsSeptember 4, 2026 | msn.comImmatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer ProgramsAugust 26, 2026 | tipranks.comImmatics N.v Share Price (IMTX.US)August 25, 2026 | lse.co.ukImmatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal MelanomaAugust 25, 2026 | seekingalpha.comImmatics Announces $150 Million Underwritten OfferingAugust 25, 2026 | globenewswire.comSee More Headlines IMTX Stock Analysis - Frequently Asked Questions How have IMTX shares performed this year? Immatics' stock was trading at $10.50 at the beginning of 2026. Since then, IMTX shares have decreased by 27.7% and is now trading at $7.59. How were Immatics' earnings last quarter? Immatics N.V. (NASDAQ:IMTX) released its quarterly earnings results on Tuesday, August, 18th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.06. The firm had revenue of $10.44 million for the quarter, compared to analysts' expectations of $12.42 million. Immatics had a negative trailing twelve-month return on equity of 47.41% and a negative net margin of 495.71%. Who are Immatics' major shareholders? Top institutional shareholders of Immatics include Doliver Advisors LP (0.02%). View institutional ownership trends. How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immatics investors own include Broadcom (AVGO), Datadog (DDOG), Advanced Micro Devices (AMD), Moderna (MRNA), Cloudflare (NET) and Qualcomm (QCOM). Company Calendar Last Earnings8/18/2026Today10/02/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 2 days ago, IMTX's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMTX CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees704Year FoundedN/APrice Target and Rating Average Price Target for Immatics$20.60 High Price Target$25.00 Low Price Target$17.00 Potential Upside/Downside+171.4%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$222.26 million Net Margins-495.71% Pretax Margin-495.98% Return on Equity-47.41% Return on Assets-39.45% Debt Debt-to-Equity RatioN/A Current Ratio7.54 Quick Ratio7.54 Sales & Book Value Annual Sales$54.60 million Price / Sales19.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.09 per share Price / Book1.86Miscellaneous Outstanding Shares136,690,000Free Float132,179,000Market Cap$1.04 billion OptionableOptionable Beta1.36 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:IMTX) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
